An AI Platform integrating imaging data and models, supporting precision care through prostate cancer’s continuum

ProCAncer-I: a H2020-funded project aimed at developing a platform to support clinical decision making in prostate cancer through medical imaging and AI

Published on: October 29, 2020
Categories: News

The Medical Imaging Research Group at IDIBGI will receive funding to carry out the ProCAncer-I project starting late 2020. The project has been recently approved by the European Commission and will be funded under the H2020 framework program.

Read more

Source: https://www.idibgi.org/ca/actualitat/procancer-i-h2020-funded-project-aimed-developing-platform-support-clinical-decision

Highlights

ProCAncer-I in the IEEE-MeMeA Conference in Taormina

ProCAncer-I in the IEEE-MeMeA Conference in Taormina

Jun 17, 2022

We are looking forward to participating it the upcoming IEEE-MeMeA Conference in Taormina! The 17th edition of IEEE International Symposium on Medical Measurements and Applications will take place in Giardini Naxos, Taormina in the metropolitan area of Messina,...

1st ProCAncer-I Project Dissemination Event in Vienna

1st ProCAncer-I Project Dissemination Event in Vienna

May 31, 2022

We are really happy to announce that we will be present at the ECR Congress in Vienna on 13 - 17 of July 2022. During the congress, a special Session will take place  on the 15th of July, presenting and discussing on the ProCAncer-I project with the title: Building...

Use Cases mapped along the prostate cancer management continuum

Use Cases mapped along the prostate cancer management continuum

Apr 6, 2022

Nowadays, prostate cancer is highly curable if detected in its early stages. Indeed, when organ-confined at diagnosis, the five-year survival rate of prostate cancer is close to 100%. Unfortunately, current prostate cancer diagnostic pipeline has several limitations. Prostate specific antigen (PSA) has a low sensitivity and specificity.

Stay in touch!